Bruno Vision Care LLC has received approval from the United States Food and Drug Administration to sell its Deseyne (vifilcon C) daily disposable contact lens with FusionTechnology in the United States.

According to the company, the Deseyne lenses integrate two patented innovations: the material of the lens (vifilcon C—an enriched hydrogel material) and the FusionTechnology delivery system. During the manufacturing process, bioactive substances known as Lachryceuticals, which include amino acids, vitamins, and polysaccharides, are embedded within the lens matrix. The company also noted that with the patented controlled release mechanism, these substances are gradually delivered from the contact lens to the anterior segment of the eye.

FusionTechnology merges hyaluronic acid with tamarind seed polysaccharides to create a natural bio-copolymer that resembles tears. This substance is released steadily, activated by body temperature, blinking, and eyelid pressure.

Bruno Vision Care brings expects the Deseyne lenses to be available to consumers in the fourth quarter of 2025.